Questions? Call 1-800-423-2090
Intended for a US Healthcare Professional Audience Only.


  1. Obizur [Prescribing Information]. Westlake Village, CA: Baxter Healthcare Corporation; October 2014.
  2. FDA approves new treatment for rare form of hemophilia [press release]. Silver Spring, MD: U.S. Food and Drug Administration; October 24, 2014.
  3. Data on file. Baxter Healthcare Corporation.
  4. Quantitative assays: the Bethesda assay. Accessed May 26, 2015.
  5. Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015;21(2):162-170.
  6. Collins P, Baudo F, Huth-Kühne A, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes. 2010;3:161.
  7. U.S. and World Population Clock. United States Government Census Web site. Accessed June 3, 2014.
  8. Franchini M, Mannucci PM. Acquired hemophilia A: a 2013 update. Thromb Haemost. 2013;110(6):1114-1120.
  9. Grethlein SJ, Besa EC, Kessler CM, et al. Acquired hemophilia. Medscape. Accessed May 18, 2015.
  10. Knoebl P, Marco P, Baudo F, et al, on behalf of the EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-631.
  11. Hemophilia: Facts. Centers for Disease Control and Prevention Web site. Accessed June 3, 2015.
  12. US National Institutes of Health Web site. Accessed September 22, 2014.